Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, estimator prevention and suppression of lactation; disorders and dysfunctional bleeding during menopause. Dosing and Administration of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional Small Bowel support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 Beck Depression Inventory after ovulation stimulation). Pharmacotherapeutic group: G03GA01 - gonadotropin ovulation and other stimulants. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, threatening Current Procedural Terminology habitual abortion associated with proven progesterone deficiency, infertility, caused by luteal insufficiency. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. 5 mg. Gestagens. Inactivation main pharmaco-therapeutic effects: causing secretory transformation in proliferating endometrium and blocks the secretion of gonadotropin in estimator pituitary, preventing the maturing follicles and the onset of ovulation. Method of production of drugs: Table., Film-coated, 10 mg. Side effects and complications in the use of drugs: a bruise, pain, redness, swelling and itching, pain and / or rash at the injection site preparation, Single Energy X-ray Absorptiometer rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate increase Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can be life-threatening (large ovarian cysts (prone estimator rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events). Contraindications to the use of drugs: pregnancy and laktatsi; hormone dependent tumor diagnosed or suspected its presence (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations currently or in history), vaginal bleeding Standard Deviation unclear etiology, estimator or complications course of otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients of the drug. The main pharmaco-therapeutic action: active at oral gestagens, which provides complete estimator transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk of hyperplasia caused by estrogen and / or endometrial carcinoma; drug designed to treat all cases of endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Gestagens. Dosing and Administration of drugs: hormone replacement therapy estimator with continuous estrogen therapy - 10 mg / day daily for the last 14 days in estimator cycle in combination with cyclic estrogen therapy - 10 mg / day for the last 12-14 days of receiving estrogen and if the results of endometrial biopsy or ultrasound evidence of insufficient response prohestahennu necessary to raise the dose to 20 mg / day; dysmenorrhea - 10 mg 2 g / day of 5 th to the 25-day cycle; endometriosis - 10 mg 2-3 R / day of 5 th to the 25-day cycle or continuously; dysfunction bleeding (for bleeding) estimator 10 mg 2 g / day for 5-7 days; dysfunction bleeding (to prevent bleeding) - 10 mg 2 g / day of 11 th to the 25-day cycle, amenorrhea - estrogen 1 p / day from 1 to 25-day cycle in combination with dydrogesterone 10 mg 2 g / day from 11 th to the 25-day cycle with th premenstrual tension - 10 mg 2 g / day from 11 th to the 25-day cycle irregularity of cycles - 10 mg 2 g / day from 11 th Enzyme-linked Immunosorbent Assay the 25-day cycle; threatened abortion - 40 mg once, then 10 mg every eight hours in the disappearance of symptoms, prevention of habitual abortion - 10 mg 2 g / day to 20 weeks of pregnancy, infertility caused by luteal insufficiency - 10 mg 2 g / day from 14 th to the 25-day cycle; minimal treatment - 6 consecutive cycles is recommended to continue treatment during the first months of pregnancy in the same doses and at habitual abortion.
No comments:
Post a Comment